| B37 | Persistence of drug-drug interaction problems with contemporary antiretroviral therapy. The case of ergotism | E-poster | Drug interactions |
| B37 | No pharmacokinetic interaction between novel NNRTI MK-8507 and Islatravir | E-poster | Drug interactions |
| B38 | Long-term efficacy among participants switched to bictegravir/emtricitabinetTenofovir alafenamide (B/F/TAF) from dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) with preexisting resistance and viral blips | E-poster | Antiretroviral drug resistance |
| B38 | Kinetics of archived M184V mutation in HIV-DNA from highly experienced HIV-infected patients with sustained viral suppression | E-poster | Antiretroviral drug resistance |
| B38 | HIV-1 subtype influences the selection of resistance mutations and the resistance level to integrase inhibitors | E-poster | Antiretroviral drug resistance |
| B39 | Week 124 results of the randomized, open-label, Phase 3 FLAIR study evaluating long-acting cabotegravir + rilpivirine for treatment in adults with HIV-1 infection (ITT-E population) | On-demand oral abstract session | Long-acting agents and other drug delivery systems |
| B39 | Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) | Oral abstract session with live Q&A | Long-acting agents and other drug delivery systems |
| B4 | Increased ability of the new lateral flow point-of-care HIV-Combo test to detect acute HIV infection in Eswatini | E-poster | HIV testing and retesting |
| B4 | Establishment of a predictor risk score for the prioritization of patients for testing for Acute HIV Infection | E-poster | HIV testing and retesting |
| B4 | Decline in HIV testing and changes in positivity rates during the COVID-19 pandemic | E-poster | HIV testing and retesting |